Accessibility Menu
Amicus Therapeutics Stock Quote

Amicus Therapeutics (NASDAQ: FOLD)

$8.55
(0.9%)
+0.08
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$8.55
Daily Change
(0.9%) +$0.08
Day's Range
$8.37 - $8.62
Previous Close
$8.55
Open
$8.48
Beta
1.01
Volume
200
Average Volume
4,763,455
Market Cap
2.6B
Market Cap / Employee
$8.55M
52wk Range
$5.51 - $12.65
Revenue
-
Gross Margin
0.89%
Dividend Yield
N/A
EPS
-$0.12
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Amicus Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
FOLD-27.97%-53.73%-14.29%-41%
S&P+14.5%+93.32%+14.09%+338%

Amicus Therapeutics Company Info

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$154.69M22.1%
Gross Profit$137.62M21.5%
Gross Margin88.97%-0.4%
Market Cap$1.76B-40.0%
Market Cap / Employee$3.54M0.0%
Employees499-3.5%
Net Income-$24.42M-55.6%
EBITDA-$5.92M-134.5%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$158.70M-24.2%
Accounts Receivable$105.85M24.3%
Inventory154.990.5%

Liabilities

Q2 2025YOY Change
Long Term Debt$434.71M-0.3%
Short Term Debt$8.61M6.1%

Ratios

Q2 2025YOY Change
Return On Assets-4.87%11.3%
Return On Invested Capital-29.66%8.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$28.93M-234.0%
Operating Free Cash Flow-$26.53M-216.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book17.8415.7312.589.12-59.45%
Price to Sales6.595.334.623.09-53.24%
Price to Tangible Book Value-86.22-76.05-116.48-85.53152.64%
Price to Free Cash Flow TTM1561.41-
Enterprise Value to EBITDA127.87167.15-442.13-334.23-279.26%
Free Cash Flow Yield0.1%-
Return on Equity-67.1%-31.7%-18.1%-22.6%-76.90%
Total Debt$444.66M$443.64M$443.47M$443.32M-0.17%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.